Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

PURPOSE: Activity estimates should be accurately evaluated in phase 2 clinical trials to ensure appropriate decisions about proceeding to phase 3 trials. RECIST v1.1. progression-free survival (PFS) is a common endpoint in oncology; however, it can be influenced by assessment criteria and trial desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R., Simes, R. John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349725/
https://www.ncbi.nlm.nih.gov/pubmed/36310299
http://dx.doi.org/10.1007/s00432-022-04404-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349725/
https://www.ncbi.nlm.nih.gov/pubmed/36310299
http://dx.doi.org/10.1007/s00432-022-04404-4

Ejemplares similares